Dysregulated Peroxiredoxins in Bladder Cancer Are Associated With an Altered Tumour Immune Microenvironment
Journal of Cellular and Molecular Medicine · 2026-03 · 30 (5)
DOI: 10.1111/jcmm.71064 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 27.02.2026. Verfasst von Jarett Wallerson und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology & Biophysics, College of Medicine, Howard University, Washington, DC, USA. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Peroxiredoxins, Tumor Microenvironment, Gene Expression Regulation, Neoplastic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Peroxiredoxins (PRDXs) are antioxidant enzymes that scavenge hydrogen peroxide and protect cells from reactive oxygen species (ROS). There are six genes encode different types of PRDXs (PRDX1–PRDX6) in humans and most of them are overexpressed in tumours; however, their expression patterns and prognostic value in bladder cancer (BLCA) remain unclear. In this study, we examined the aberrant expression of all six types of PRDX genes in BLCA and identified distinct clinical and immune associations. High expression of PRDX1 and PRDX6 was correlated with poor overall survival (OS), increased mutational burden and chromosomal instability. Overexpression of PRDX4 and PRDX6 was associated with advanced tumour stage, larger tumour size, higher immune scores, and increased immune cell infiltration. By contrast, PRDX2 overexpression showed only modest effects on OS and was associated with reduced immune signalling and diminished infiltration of anti‐tumor immune cells. These findings highlight the differential roles of PRDX family members in shaping BLCA tumour immune microenvironment. PRDXs may serve as prognostic biomarkers for patients tratification and represent potential therapeutic targets to enhance immunotherapy response. Further in vitro and in vivo studies are required to confirm our in silico data and define their clinical relevance for BLCA prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Physiology & Biophysics, College of Medicine, Howard University, Washington, DC, USA.
- Department of Biology, Howard University, Washington, DC, USA.
Förderung
- NCI NIH HHS
- NIH HHS
- National Cancer Institute
- National Institutes of Health
Zitieren
APA
Wallerson, J., Rostampour, S., Teng, S., & Kidane, D. (2026). Dysregulated Peroxiredoxins in Bladder Cancer Are Associated With an Altered Tumour Immune Microenvironment. Journal of Cellular and Molecular Medicine, 30(5). https://doi.org/10.1111/jcmm.71064
Vancouver
Wallerson J, Rostampour S, Teng S, Kidane D. Dysregulated Peroxiredoxins in Bladder Cancer Are Associated With an Altered Tumour Immune Microenvironment. Journal of Cellular and Molecular Medicine. 2026;30(5). doi:10.1111/jcmm.71064
BibTeX
@article{Wallerson2026,
author = {Wallerson, Jarett and Rostampour, Sara and Teng, Shaolei and Kidane, Dawit},
title = {Dysregulated Peroxiredoxins in Bladder Cancer Are Associated With an Altered Tumour Immune Microenvironment},
journal = {Journal of Cellular and Molecular Medicine},
year = {2026},
volume = {30},
number = {5},
doi = {10.1111/jcmm.71064}
}
EUVIMED